Ipsen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IPSEN, and what generic alternatives to IPSEN drugs are available?
IPSEN has four approved drugs.
There are thirty-four US patents protecting IPSEN drugs.
There are two hundred and seventy-five patent family members on IPSEN drugs in forty-six countries and twenty-six supplementary protection certificates in fifteen countries.
Drugs and US Patents for Ipsen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | 10,093,697 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-001 | Aug 30, 2007 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | 11,583,539 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ipsen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-002 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-001 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-003 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ipsen Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 103260625 | ⤷ Try a Trial |
Japan | 2019116517 | ⤷ Try a Trial |
Norway | 345218 | ⤷ Try a Trial |
Brazil | 122021024957 | ⤷ Try a Trial |
Croatia | P20201338 | ⤷ Try a Trial |
South Korea | 20180063255 | ⤷ Try a Trial |
Brazil | 112014031088 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ipsen Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1746976 | 1790033-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008 |
3400944 | CA 2022 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719 |
1746976 | 2017/029 | Ireland | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REGISTRATION NO/DATE: EU/1/16/1130 20161014 |
1746976 | 2017C/027 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
1746976 | SPC/GB17/043 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REGISTERED: UK EU/1/16/1130 20161018 |
1746976 | CR 2017 00030 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REG. NO/DATE: EU/1/16/1130 20161018 |
3400944 | 2021054 | Norway | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT; REG. NO/DATE: EU/1/21/1566 20210805 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.